| Q2 2024 |
66 |
$405M |
+$125M |
-$72.9M |
+$51.6M |
MRUS, NUVL, RNA, URGN, ERAS
|
13F-HR |
8/14/2024, 01:44 PM |
| Q1 2024 |
68 |
$340M |
+$110M |
-$143M |
-$33.6M |
MRUS, SLDB, MORF, ORIC, MRSN
|
13F-HR |
5/14/2024, 05:37 PM |
| Q4 2023 |
64 |
$324M |
+$140M |
-$129M |
+$10.8M |
MRUS, MRSN, MORF, NUVL, PSTX
|
13F-HR |
2/14/2024, 10:28 AM |
| Q3 2023 |
103 |
$328M |
+$132M |
-$93.7M |
+$38.6M |
XBI, IMGN, MORF, MRUS, SLNO
|
13F-HR |
11/13/2023, 09:29 AM |
| Q2 2023 |
97 |
$323M |
+$132M |
-$70.5M |
+$61.3M |
IMGN, MRUS, MORF, SDGR, KRYS
|
13F-HR |
8/14/2023, 10:53 AM |
| Q1 2023 |
71 |
$242M |
+$101M |
-$63.9M |
+$37.2M |
MRUS, MGNX, VRAYQ, PSTX, ORIC
|
13F-HR |
5/15/2023, 09:57 AM |
| Q4 2022 |
90 |
$350M |
+$127M |
-$46.8M |
+$80.2M |
RXDX, MDGL, BLU, PSTX, VRAYQ
|
13F-HR |
2/14/2023, 11:29 AM |
| Q3 2022 |
78 |
$296M |
+$97.3M |
-$53M |
+$44.3M |
BLU, RLMD, RXDX, VCYT, AKRO
|
13F-HR |
10/28/2022, 05:06 PM |
| Q2 2022 |
68 |
$325M |
+$176M |
-$29.6M |
+$147M |
QQQ, ITCI, XBI, BLU, VCYT
|
13F-HR |
7/25/2022, 03:27 PM |
| Q1 2022 |
58 |
$205M |
+$58.6M |
-$15.4M |
+$43.2M |
XBI, ITCI, SRRA, VCYT, CTIC
|
13F-HR |
5/13/2022, 04:32 PM |
| Q4 2021 |
71 |
$247M |
+$107M |
-$12.7M |
+$94.4M |
XBI, IMGN, BHVNXXXX, ITCI, MRUS
|
13F-HR |
2/14/2022, 08:12 AM |
| Q3 2021 |
78 |
$173M |
+$46.5M |
-$60.1M |
-$13.6M |
BHVNXXXX, VCYT, MRTX, MRUS, AMYT
|
13F-HR |
11/15/2021, 03:01 PM |
| Q2 2021 |
87 |
$187M |
+$75.4M |
-$60.7M |
+$14.7M |
DRNA, MRUS, MRTX, VCYT, MORF
|
13F-HR |
8/16/2021, 03:24 PM |
| Q1 2021 |
88 |
$178M |
+$63.8M |
-$55M |
+$8.85M |
ACRS, CRIS, VCEL, INSM, AMYT
|
13F-HR |
5/17/2021, 06:02 PM |
| Q4 2020 |
83 |
$172M |
|
|
|
VCEL, ITCI, DCTH, INSM, AMYT
|
13F-HR |
2/16/2021, 04:09 PM |